Background： Transcription factor 7-like 2 （TCF7L2）-rs7903146 polymorphism is associated with increased risk of type 2 diabetes. The response of insulin and insulin resistance to artichoke leaf extract （ALE） may b...Background： Transcription factor 7-like 2 （TCF7L2）-rs7903146 polymorphism is associated with increased risk of type 2 diabetes. The response of insulin and insulin resistance to artichoke leaf extract （ALE） may be affected by TCF7L2-rs7903146 polymorphism. Objective： This study examined the effects of ALE supplementation on metabolic parameters of the TCF7L2-rs7903146 polymorphism in patients with metabolic syndrome （MetS）. Design, setting, participants and interventions： This double-blind clinical trial was conducted on 80 patients with MetS in Sina Clinic, Khoy, Iran. The patients were randomized into ALE or placebo groups to receive either ALE （1800 mg/d as four tablets） or matching placebo for 12 weeks. Main outcome rneasures： Anthropometric indices, blood pressure, glucose and lipid profile levels were measured before and after the study. Moreover, patients were genotyped for TCF7L2 polymorphism. Results： ALE supplementation decreased insulin level and the homeostasis model assessment of insulin resistance （HOMA-IR） in patients with the ＂IT genotype of TCF7L2-rs7903146 polymorphism （P 〈 0.05）. There was no significant interaction between blood pressure, glucose and lipid profile response to ALE supplementation. Conclusion： The responses of insulin and HOMA-lR to ALE supplementation have shown an interaction with single-nucleotide polymorphism rs7903146 in TCF7L2. Trial registration： Iranian Registry of Clinical Trial IRCT201409033320N9.展开更多
基金supported by a Grant from the Research Vice Chancellor, Tabriz University of Medical Sciences, Tabriz, Iran (grant number: 5/97/4653)
文摘Background： Transcription factor 7-like 2 （TCF7L2）-rs7903146 polymorphism is associated with increased risk of type 2 diabetes. The response of insulin and insulin resistance to artichoke leaf extract （ALE） may be affected by TCF7L2-rs7903146 polymorphism. Objective： This study examined the effects of ALE supplementation on metabolic parameters of the TCF7L2-rs7903146 polymorphism in patients with metabolic syndrome （MetS）. Design, setting, participants and interventions： This double-blind clinical trial was conducted on 80 patients with MetS in Sina Clinic, Khoy, Iran. The patients were randomized into ALE or placebo groups to receive either ALE （1800 mg/d as four tablets） or matching placebo for 12 weeks. Main outcome rneasures： Anthropometric indices, blood pressure, glucose and lipid profile levels were measured before and after the study. Moreover, patients were genotyped for TCF7L2 polymorphism. Results： ALE supplementation decreased insulin level and the homeostasis model assessment of insulin resistance （HOMA-IR） in patients with the ＂IT genotype of TCF7L2-rs7903146 polymorphism （P 〈 0.05）. There was no significant interaction between blood pressure, glucose and lipid profile response to ALE supplementation. Conclusion： The responses of insulin and HOMA-lR to ALE supplementation have shown an interaction with single-nucleotide polymorphism rs7903146 in TCF7L2. Trial registration： Iranian Registry of Clinical Trial IRCT201409033320N9.
